ABL News

November 5, 2020

ABL Europe, University Clinic of Tuebingen and Prime Vector Technologies partner for a 2nd generation COVID-19 vaccine

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

June 8, 2020

JUST – EVOTEC BIOLOGICS PARTNERS WITH ABL ON DEVELOPMENT OF BROADLY NEUTRALISING ANTIBODY AGAINST HIV

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

May 11, 2020

Themis collaborates with ABL Europe to manufacture its SARS-CoV-2 Vaccine Candidate in France

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

April 27, 2020

ABL Continues to Support Race to find a Cure; SARS-CoV-2 (COVID-19) Vaccine Candidate

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

April 15, 2020

ABL, Inc. Supports Fill/Finish of SARS-CoV-2 (COVID-19) Vaccine Candidate

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

October 4, 2019

ABL, Inc. Awarded Multiple-Award IDIQ Contract to Provide cGMP Manufacturing Services in support of the PREVENT Cancer Preclinical Cancer Prevention Program – First Manufacturing Task Order Awarded

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

November 19, 2018

ABL Expands GMP Viral Vector Manufacturing Capacity with State-of-the-Art Facility Acquisition in Lyon, France

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

November 12, 2018

ABL, Inc. Announces Appointment of Jarlath Keating as President and Chief Executive Officer

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

October 3, 2018

ABL Awarded Long-Running National Cancer Institute Contract to Continue Groundbreaking Retroviral Research

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

September 26, 2018

ABL, Inc. Announces Hiring of Jarlath Keating as Chief Commercial Officer

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

June 4, 2018

ABL, Inc. Announces Hiring of Marykay Marchigiani as Chief Financial Officer

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

March 16, 2018

Sartorius Stedim Biotech Supports ABL Europe in Successful Completion of Viral Vector GMP Capacity Expansion

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

March 5, 2018

Najít Technologies Partners with ABL for Development of Novel Vaccine Platform

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

February 27, 2018

ABL Europe Enters into a Collaboration for the GMP Manufacture of Hookipa Biotech’s Heterologous Viral Vector Immunotherapy Platform

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

January 23, 2018

ABL Europe and SillaJen Expand Strategic Manufacturing Collaboration for Oncolytic Virus Therapies

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

July 19, 2017

ABL Awarded NIH Contract for HIV Vaccine Development Worth Up to $318 Million

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

May 17, 2017

ABL, Inc. is a Finalist for the Maryland Tech Council Life Science Company of the Year

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

May 11, 2017

ABL Increases Aseptic Fill/Finish Capacity with State-of-the-Art, Fully Automated Vial Filling Line

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

April 19, 2017

The National Center for Advancing Translational Sciences (NCATS) Awards ABL a 5-Year Therapeutic Development and Manufacturing Contract

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

April 5, 2017

ABL Awarded BARDA Contract to Fill Live Virus-Based Medical Countermeasures

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

February 22, 2017

ABL Nominated for Two Vaccine Industry Excellence Awards: Best CMO & Best CRO

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

September 21, 2016

ABL Awarded NIAID Contract to Develop Biotherapeutics to Address Infectious Disease

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

August 4, 2016

ABL Awarded Subcontract for the Production of an Inactivated Zika Virus Vaccine

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

July 26, 2016

The Division of AIDS Awards ABL a Seven-Year Contract to Provide HIV Microbicide Research and Product Development Support

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

May 24, 2016

ABL, Inc. Announces Agreements with REGENXBIO for Process Development, Scale-Up and Clinical Manufacturing of RGX-501

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

May 16, 2016

SillaJen Announces Commercial Manufacturing Agreement with ABL Europe For Lead Oncolytic Virus, Pexa-Vec

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

March 11, 2016

ABL Awarded 3-Year Program Extension as the Biologics Production Facility for NHLBI’s SMARTT Program

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

March 3, 2016

ABL Part of Team Awarded $900 Million IDIQ Contract by U.S. Army for Medical Product Research and Development

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

February 18, 2016

ABL, Inc. Launches Virus Manufacturing Operations in Europe

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

February 3, 2016

Transgene and ABL Announce the Acquisition by ABL Europe of Transgene’s Production Asset

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

January 14, 2016

ABL, Inc. Offers Quanterix Diagnostic Platform for Ultrasensitive Biomarker Detection Through Platine Pharma Services Subsidiary

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

July 10, 2015

ABL Named Small Business Champion by Montgomery County

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

June 30, 2015

ABL Successfully Completes Drug Product Manufacture of Ebola Vaccine for Clinical Trial

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

March 24, 2015

ABL Awarded National Cancer Institute Contract to Continue Groundbreaking Retroviral Research

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

February 13, 2015

ABL Recognized for Supporting Fill-Finish of Novavax’s Zaire Ebolavirus Glycoprotein Nanoparticle Vaccine

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

January 20, 2015

ABL Selected to Support Glioblastoma Multiforme Trial with Clinical Testing Services

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

August 18, 2014

Expression Therapeutics Selects ABL for Development of Hemophilia A Factor VIII Therapy

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

July 21, 2014

ABL, Inc. Acquires Majority Interest in Platine Pharma Services

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

March 4, 2014

ABL supports Profectus BioSciences with preclinical efficacy studies for its subunit vaccine for HIV, IHV001

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

January 24, 2014

Dr. Thomas VanCott Invited to Speak at 11th Annual Biologics Forum in Tokyo

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

December 24, 2013

Statement from ABL President and CEO Dr. Thomas VanCott on Strategic Agreement with Bioqual

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

November 6, 2013

ABL Completes Manufacture of Rhabdovirus-Based Oncolytic Therapeutic Vaccine for Phase I Clinical Trial

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

October 30, 2013

ABL, Inc. and CALIXAR Announce Strategic Marketing Agreement

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

October 1, 2013

ABL Selected by PATH to Manufacture Novel Shigella Vaccine Candidate

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

June 19, 2013

Dr. Maria Grazia Ferrari Spoke at the NMRC on Her Mucosal Immunology Research

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

June 12, 2013

ABL To Attend Biodefense Vaccines and Therapeutics Summit

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

June 4, 2013

ABL Awarded Simian Vaccine Evaluation Unit (SVEU) Contract with NIAID Worth Up To $80M

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

May 1, 2013

ABL Wins 7-Year NIAID Simian Vaccine Evaluation Unit Contract

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

April 11, 2013

ABL President and CEO Dr. Thomas VanCott Named Finalist for Tech Council of Maryland (TCM) 2013 Executive of the Year

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

March 29, 2013

ABL President and CEO Dr. Thomas VanCott is a Finalist for Executive of the Year

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

February 19, 2013

ABL Recognized for Biologics Manufacturing in Support of NHLBI-Sponsored IND

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

January 8, 2013

ABL 2012 Publications and Presentations

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

November 6, 2012

ABL Announces Additions to Manufacturing and Quality Control Teams

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

August 1, 2012

ABL Awarded NIH Contract to Fund up to $102M in Biologics Manufacturing and Characterization Services

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

July 25, 2012

ABL Awarded DMID Biologics Manufacturing Contract Worth Up to $102M

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

June 12, 2012

ABL to Provide Cell Line Development, Process Development, and cGMP Manufacturing Services of scuPA for The University of Texas Health Science Center at Tyler

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

February 14, 2012

ABL Supporting Manufacture of AlphaCores rhLCAT Protein through NHLBIs SMARTT Program

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

February 8, 2012

Inviragen Enlists ABL for Manufacture of Master Virus Seed Stock for Plague Vaccine Development

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

January 10, 2012

Trophogen Selects ABL as Contract Manufacturer for Recombinant, Human Follicle-Stimulating Hormone (rhFSH) Analog

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

November 14, 2011

ABL Launches New Website

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

September 14, 2011

ABL Awarded “NIAID Preclinical Development Support” Contract with Maximum Funding of $102M Over Seven Years

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

August 28, 2011

ABL Completes Validation of New cGMP Manufacturing Facility

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

June 20, 2011

ABL Selected to Collaborate on a 5-Year U19 Grant in Support of New Research toward an HIV Cure

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

June 6, 2011

Contract Pharma: ABL Opens Newly Expanded HQ

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

June 5, 2011

Washington Post – Biotech Consultants Find Fertile Ground in the DC Area

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

June 3, 2011

BioWatch: ABL Turns 50 with New Digs, Open House

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

March 30, 2011

ABL Inc. Awarded the NIH Contract for NHP Core Quantitative Viral RNA Laboratory for AIDS Vaccine Research and Development

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

January 6, 2011

Advanced BioScience Laboratories Selected as the NHLBI Biologics Manufacturing Facility for New SMARTT Program

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.